Bedinvetmab in Dogs

Bedinvetmab is the generic name for Librela, a prescription injectable medication used to control pain associated with osteoarthritis in dogs. It is a monoclonal antibody, which means it is a targeted protein therapy rather than a traditional anti-inflammatory drug. In the United States, the FDA approved Librela on May 5, 2023 for dogs with osteoarthritis pain, and it is given by your vet as a subcutaneous injection about once every month.

For many dogs, osteoarthritis causes stiffness, limping, slower walks, trouble rising, and less interest in play. Bedinvetmab can be helpful because it targets one part of the pain pathway linked to arthritis. Some dogs improve noticeably in comfort and mobility, while others need a broader plan that may also include weight management, rehabilitation, home changes, joint-support strategies, or other medications. Response varies, so your vet will usually judge success by changes in daily function, not by one injection alone.

This medication is not a cure for arthritis, and it is not the right fit for every dog with pain. It has been studied for osteoarthritis pain, especially in limb joints, not for every cause of lameness or neurologic disease. Your vet may recommend an exam, gait assessment, and sometimes bloodwork or imaging before starting treatment, especially if your dog has other medical problems or if the source of pain is not clear.

Bedinvetmab works by binding to nerve growth factor, often shortened to NGF. NGF is involved in pain signaling and sensitization in osteoarthritis. When bedinvetmab attaches to NGF, it reduces NGF’s ability to activate pain pathways. In practical terms, that can lower arthritis-related pain and help some dogs move more comfortably.

This is different from how NSAIDs work. NSAIDs mainly reduce inflammatory pathways, while anti-NGF monoclonal antibodies target a pain-signaling pathway. Because of that difference, bedinvetmab may be considered when a dog cannot tolerate some oral pain medicines, or it may be used as part of a multimodal plan if your vet feels the combination is appropriate. Merck notes that a drug-drug interaction between anti-NGF monoclonal antibodies and NSAIDs is not known to occur in dogs, although any combined plan still needs veterinary oversight.

The medication is long-acting, so it is labeled for dosing every 30 days. Improvement is not always immediate. Some dogs show better mobility after the first injection, while others need more time and reassessment. Your vet may also recommend a gradual return-to-activity plan, because dogs that feel better can sometimes do too much too quickly.

Like any prescription medication, bedinvetmab can cause side effects. Reported reactions from prescribing and reference materials include injection-site discomfort or dermatitis, bacterial skin infection, urinary tract infection, vomiting, weight loss, abnormal urination, and increased blood urea nitrogen on labwork. Some dogs also lose response over time, which may reflect disease progression or reduced effectiveness for that individual dog.

After wider use in the United States, the FDA reviewed post-approval adverse event reports and highlighted additional reported problems, including ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, and polydipsia. The FDA also noted that in some reports, death, including euthanasia, was an outcome. These reports do not prove that Librela caused every event, because adverse event reporting can include underlying disease, other medications, or unrelated illness. Still, they are important enough that pet parents should discuss risks and monitoring with your vet before each injection.

See your vet immediately if your dog develops collapse, seizures, marked weakness, trouble walking, severe vomiting or diarrhea, inability to rise, sudden urinary accidents, or major behavior changes after treatment. Even milder changes matter. If your dog seems more thirsty, more wobbly, less interested in food, or unusually tired, contact your vet promptly so they can decide whether monitoring, testing, or a change in the treatment plan makes sense.

Bedinvetmab is given by your vet as a subcutaneous injection once every 30 days. Dosing is based on body weight, and the product is not intended for home administration by pet parents. In clinical references, bedinvetmab is commonly listed at 0.5 mg/kg subcutaneously every 30 days, with vial selection based on the dog’s weight and the available product concentrations.

Because this is a monthly injection, timing matters. If an appointment is missed, contact your vet to reschedule rather than trying to stretch the interval indefinitely. Your vet will also want to know how your dog did after the last dose, including mobility changes, appetite, thirst, urination, and any neurologic signs. That history helps guide whether to continue, pause, or adjust the overall arthritis plan.

Bedinvetmab should only be used under veterinary supervision. Pet medication references note it should not be used in dogs with known hypersensitivity to bedinvetmab, and it has not been evaluated in breeding, pregnant, or lactating dogs. It also has not been evaluated in dogs younger than 12 months or in dogs with a recent cruciate ligament rupture. Those details matter when your vet is deciding whether this medication fits your dog’s full medical picture.

Published veterinary references do not identify a known direct drug-drug interaction between anti-NGF monoclonal antibodies like bedinvetmab and NSAIDs in dogs. Merck specifically notes that such an interaction is not known to occur, and some dogs may benefit from both approaches as part of multimodal pain control. That said, combination therapy is still a case-by-case decision because the dog’s age, kidney values, liver health, neurologic history, and other medications all matter.

Your vet should review every product your dog receives, including prescription drugs, supplements, joint products, CBD products, and over-the-counter items. Even if bedinvetmab itself is not processed like a typical oral drug, the overall treatment plan can still become complicated. For example, a dog on an NSAID may need lab monitoring for the NSAID, while a dog with new weakness or urinary changes may need a different workup before the next injection.

It is also important not to assume that all pain is arthritis pain. If a dog has spinal disease, a torn ligament, or another orthopedic problem, your vet may choose a different plan or add other therapies instead of relying on bedinvetmab alone. Tell your vet about any new limping, knuckling, stumbling, or behavior changes before the next dose.